No Data
Limit up during the day and a warning at night? JiangSu WuZhong Pharmaceutical Development's annual report may receive an audit report with an inability to express an opinion | Quick read of the announcement.
① Due to various reasons such as overdue accounts receivable and receivables overdue in the trade business, JiangSu WuZhong Pharmaceutical Development does not rule out the possibility of receiving an audit report expressing an inability to issue an opinion in the 2024 report. ② In addition to being investigated for violations of information disclosure and multiple Bearish factors, JiangSu WuZhong is currently in a precarious situation.
On April 24, A-share investment warning: Liaoning Energy Industry Shareholder Shenzhen Xianglong intends to reduce its shareholding by no more than 3%; JiangSu WuZhong Pharmaceutical Development may face delisting risk warning.
Shareholders of Hengxing New Material, Jinpu Guodiao and Su Shang Investment, plan to collectively reduce their holdings by no more than 3.00%; shareholders of Liaoning Energy, Shenzhen Xianglong, intend to reduce their holdings by no more than 3%; shareholders of Lingdian Electronic Control, Tan Chun, plan to reduce their holdings by no more than 1.131%; Guangdong Zhongnan Iron & Steel is expected to report a net loss of 1.204 billion yuan for 2024; Guangzhou Zhiguang Electric is expected to report a net loss of 0.326 billion yuan for 2024; Changsha DIALINE New Material Sci.&Tech. is expected to report a net loss of 0.244 billion yuan for 2024; Suzhou Harmontronics Automation Technology is expected to report a net loss of 1.103 billion yuan for 2024; JiangSu WuZhong Pharmaceutical Development may be subject to a Delisted risk warning.
JiangSu WuZhong Pharmaceutical Development (600200.SH): May be subject to delisting risk warning.
On April 23, Gelonghui reported that JiangSu WuZhong Pharmaceutical Development (600200.SH) announced that the company is under investigation by the China Securities Regulatory Commission (hereinafter referred to as "CSRC"). If the subsequent facts determined by the CSRC result in administrative penalties that fall under the major illegal delisting circumstances stipulated in the Shanghai Stock Exchange's stock listing rules, even if the company achieves profitability in 2024, its stocks will still be subject to mandatory delisting due to significant violations. Preliminary communication with the annual audit firm Zhongxing Cai Guanghua Certified Public Accountants indicates that the company's 2024 financial report may not exclude the possibility of receiving an audit report with an inability to express an opinion. Currently,
JiangSu WuZhong Pharmaceutical Development's subsidiary is in trouble, with financial loan defaults leading to the freezing of over 30 bank accounts | Quick read of the announcement.
① JiangSu WuZhong Pharmaceutical Development's subsidiary has had its Bank Account frozen due to overdue loans, which may subsequently impact some of its Business. ② A violation of information disclosure has led to a formal investigation, and a subsidiary has been sued. Within two months, JiangSu WuZhong, which once became very popular for holding the "youthful needle," is now facing continuous troubles.
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Investors Aren't Buying JiangSu WuZhong Pharmaceutical Development Co., Ltd.'s (SHSE:600200) Revenues
